Recombinant Human FABP4 Protein (N-6His)

Name: Recombinant Human FABP4 Protein (N-6His)
Brand: Beta LifeScience
SKU: BL-0338NP
Availability: InStock

BL-0338NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Collections: High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Fatty Acid-Binding Protein 4 is produced by our E.coli expression system and the target gene encoding Cys2-Ala132 is expressed with a 6His tag at the N-terminus.
Accession	P15090
Synonym	Fatty Acid-Binding Protein Adipocyte; Adipocyte Lipid-Binding Protein; ALBP; Adipocyte-Type Fatty Acid-Binding Protein; A-FABP; AFABP; Fatty Acid-Binding Protein 4
Gene Background	Fatty Acid-Binding Protein 4 (FABP4) is a cytoplasm protein that belongs to the fatty-acid binding protein (FABP) family of calycin superfamily. Fatty acid binding proteins are a family of small, highly conserved, cytoplasmic proteins that bind long-chain fatty acids. FABP4 is expressed in a differentiation-dependent fashion in adipocytes and is a critical gene in the regulation of the biological function of these cells. FABP4 is thought to participate in Lipid transport protein in adipocytes. FABP4 binds to the long chain fatty acids and retinoic acid, delivers long-chain fatty acids and retinoic acid to their cognate receptors in the nucleus. FABP4 modulates inflammatory responses and cholesterol ester accumulation. FABP4 is a plasma marker of metabolic disturbances in HIV-infected patients, and therefore, could serve to guide therapeutic intervention in this group of patients.
Molecular Mass	16.88 KDa
Apmol Mass	15 KDa, reducing conditions
Formulation	Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.
Endotoxin	Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Purity	Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity	Not tested
Reconstitution	Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Usage	For Research Use Only

Target Details

Target Function	Lipid transport protein in adipocytes. Binds both long chain fatty acids and retinoic acid. Delivers long-chain fatty acids and retinoic acid to their cognate receptors in the nucleus.
Subcellular Location	Cytoplasm. Nucleus.
Protein Families	Calycin superfamily, Fatty-acid binding protein (FABP) family
Database References	HGNC: 3559 OMIM: 600434 KEGG: hsa:2167 STRING: 9606.ENSP00000256104 UniGene: PMID: 29305311 association between serum FABP4 concentrations and sarcopenia in chronic hemodialysis patients PMID: 29935964 intermittent high glucose potentiates A-FABP activation and inflammatory responses via TLR4/p-JNK signaling in THP-1 cells PMID: 29850615 High serum A-FABP concentration is associated with peripheral arterial disease in women, but not men, with type 2 diabetes mellitus. PMID: 28303680 FABP4 from adipocytes mediate adipocyte-cholangiocarcinoma interactions that are crucial for the invasion, migration and epithelial-mesenchymal transition of cholangiocarcinoma cells PMID: 29237483 Compared with the low arterial stiffness group, the high arterial stiffness group had higher values for age, systolic blood pressure, pulse pressure, duration of kidney transplantation and serum A-FABP PMID: 28660445 Blood FABP4 is a biomarker for metabolic syndrome and cardiovascular disease independently of HIV status and antiretroviral therapy. PMID: 29304747 Increased FABP4 blood level is a biomarker of lead exposure in women. PMID: 29264639 ubiquitylation destabilizes the fold of two proteins, FKBP12 and FABP4 PMID: 27991582 Compared to control group, breast cancer patients show higher FABP4 and FABP5 blood levels. Our data suggest that, particularly, circulating FABP4 levels could be considered a new independent breast cancer biomarker. Our work translates basic science data to clinic linking the relationship between adipose tissue and lipid metabolism to breast cancer. PMID: 28701570 findings reveal a pro-angiogenic role of FABP4 in first trimester placental trophoblast cells and its regulation may have impact in placental physiology. PMID: 28620819 A-FABP concentration was an independent predictor of cardiovascular events in patients with stable angina undergoing percutaneous coronary intervention. PMID: 29017449 Ectopic expression and secretion of FABP4 in vascular endothelial cells contribute to neointima formation after vascular injury. PMID: 28903937 Elevated A-FABP concentration could be a predictor for MetS and arterial stiffness in hypertensive patients PMID: 28860092 The present study demonstrated that the androgen was correlated with the serum A-FABP levels negatively in men, but positively in women. PMID: 27270834 Increased second trimester plasma FABP4 independently predicted GH/PE in GDM patients PMID: 29394285 our research demonstrated that high FABP3 or FABP4 expression had strong prognostic value for overall survival in non-small cell lung cancer PMID: 27323829 The distribution of genotype frequencies in the assessed women (PON1 Q192R polymorphism) was QQ = 20%, QR = 48% and RR = 32%. Significantly higher serum FABP4 levels were found in women with genotype QR/RR (20.6 +/- 2.20 ng/mL), when compared with the levels found in the QQ group (12.8 +/- 1.70 ng/mL) (p = .004). PMID: 27712128 serum A-FABP levels were increased significantly in normoglycemic individuals with a first-degree family history of diabetes; the use of serum A-FABP as a biomarker in the first-degree relatives of patients with diabetes may result in overestimation of the risk of obesity-induced metabolic disease and cardiovascular disease PMID: 27534843 Findings in the dorsolateral prefrontal cortex in schizophrenia provide evidence of altered proteins involved in synaptic function (FABP4), cytoarchitecture organization (NEFH), and circadian molecular clock signaling (CSNK1E), which may be contributing to the cognitive and/or negative symptoms in this disorder. FABP4, CSNK1E and NEFH could become potentially useful biomarkers for schizophrenia. PMID: 27236410 Circulating levels of AFABP and EFABP are not decreased in Lipodystrophy despite adipose tissue loss in contrast to other adipokines including leptin and adiponectin. PMID: 28088613 Taken together, PPAR gamma and FABP4 gene expression levels in PBMCs [peripheral blood mononuclear cells] may be indicators of metabolic factors and body composition components. PMID: 27563749 eFABP4 induces ER stress and potentiates the effect of linoleic acid in HepG2 cells, suggesting that FABP4 could be a link between obesity-associated metabolic abnormalities and hepatic insulin resistance mechanisms PMID: 27155388 Increased second-trimester FABP4 independently predicted pre-eclampsia in women with type 1 diabete and significantly improved reclassification and discrimination. PMID: 27630211 High levels of FABP4 are significantly related to stroke risk and severity, independent from other traditional and emerging risk factors, suggesting that they may play a role in stroke pathogenesis. PMID: 28781090 We found that serum FABP4 concentration were associated with insulin resistance and secretion in type 2 diabetes mellitus. This suggests that FABP4 may play an important role in glucose homeostasis. PMID: 28654680 High FABP4 expression is associated with ovarian cancer. PMID: 27568980 AFABP levels were higher in neonates compared with adults. Preterm infants had higher AFABP levels compared with full-term infants. Among full-term infants, AFABP levels in SGA infants were lower, compared with appropriate for gestational age and large for gestational age infants. PMID: 28324040 Exogenous FABP4 plays a key role in tumor proliferation and activates the expression of fatty acid transport proteins in MCF-7 breast cancer cells. PMID: 27061264 High FABP4 expression is associated with Acute Monocytic Leukemia. PMID: 28108519 FABP4 over-expression in cardiomyocytes can aggravate the development of cardiac hypertrophy through the activation of ERK signal pathway. PMID: 27294862 Results show that serum FABP4 levels were significantly increased in patients with psoriasis. PMID: 27864793 secreted FABP4 and FABP5 from adipocytes as adipokines differentially affect transcriptional and metabolic regulation in ADSC near adipocytes PMID: 27936164 FABP4 locally produced by epicardial/perivascular fat and macrophages in vascular plaques contributes to the development of coronary atherosclerosis. PMID: 27013610 Elevated levels of FABP4 are associated with higher cardiovascular mortality among men with type 2 diabetes. PMID: 27609367 These genes should be at the downstream of signal pathways and be regulated by the 23 genes identified before. Our findings may provide a unique new model for studying the molecular control of cattle cross-talk between adipose and skeletal muscle. PMID: 27856250 higher serum A-FABP level is positively associated with MetS in type 2 DM patients PMID: 28042581 FABP4 level was independently associated with gender, adiposity, renal dysfunction, and levels of cholesterol. PMID: 27241838 FABP4 DNA hypomethylation induced by Hcy may be involved in the overexpression of FABP4, thereby inducing cholesterol accumulation in macrophages. PMID: 27221153 Study found that the fasting insulin and age-adjusted AFABP concentrations were significantly higher in the gestational diabetes mellitus group of women compared with the normal glucose tolerance participants in the mid- and late stages of pregnancy. PMID: 27181269 mTOR/FABP4 signaling pathway directly regulates the proliferation of endothelial cells in hemangioma. Rapamycin and inhibitors of FABP4 have therapeutic potential for treating infantile hemangiomas. PMID: 27914823 Results suggested that the expression of a lipid metabolism-related gene and an important SNP in the 3'-UTR of FABP4 are associated with TNBC prognosis. PMID: 26959740 In multiple linear regression stepwise analysis, BMI, HbA1C, and HOMA-IR were significantly independent determinants for A-FABP. BMI, HbA1C, and HOMA-IR are independently associated with A-FABP in obese subjects with newly diagnosed type 2 diabetes. A-FABP may be related to insulin resistance and inflammation in type 2 diabetes and concomitant obesity. PMID: 27819006 The increase in placental FABP4 expression in preeclampsia may affect the function of trophoblast, and this increase may have a role in the pathogenesis of preeclampsia. PMID: 26992681 our findings set up a novel mechanism for FABP4, adipsin and adiponectin through gut microbiota mediating expression in gut Paneth cells. PMID: 26687459 results underline a gender difference in FABP4 secretion in stable COPD patients. PMID: 26823558 Increased FABP4 level showed increased risk for reduced lung function in subjects with normal ventilatory function. PMID: 26887419 High FABP expression is associated with Sepsis. PMID: 27089280 Serum irisin might exert antagonistic effects on FABP4 in the middle-aged Chinese population. PMID: 26752184 Urinary FABP4 level is independently correlated with level of albuminuria and possibly predicts yearly decline of estimated glomerular filtration rate. Urinary FABP4 would be a novel biomarker of glomerular damage. PMID: 25506691

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.